AstraZeneca's Forxiga (dapagliflozin) Receives MHLW's Approval for Chronic Heart Failure
Shots:
- The approval is based on a DAPA-HF trial assessing Forxiga (10mg- qd) + SOC vs PBO + SOC in 4-744 patients with HFrEF (LVEF ≤ 40%) with/ out T2D
- The study demonstrated reduced the risk of the composite outcome by 26% along with a reduction in the risk of CV death or worsening of HF events- including hospitalization for HF
- Additionally- Forxiga is currently being tested for HFpEF in the P-III DELIVER trial with data readout anticipated in the H2’21
Ref: PRNewswire | Image: Mint
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com